For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Organon & Co (NYSE: OGN) was $6.34 for the day, down -4.80% from the previous closing price of $6.66. In other words, the price has decreased by -$4.80 from its previous closing price. On the day, 11.31 million shares were traded. OGN stock price reached its highest trading level at $6.84 during the session, while it also had its lowest trading level at $6.32.
Ratios:
Our analysis of OGN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.50. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 12.14 whereas as Long-Term Debt/Eq ratio is at 11.98.
JP Morgan Downgraded its Neutral to Underweight on September 06, 2024, whereas the target price for the stock was revised from $18 to $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 14 ’25 when COX CARRIE SMITH bought 12,469 shares for $8.07 per share. The transaction valued at 100,591 led to the insider holds 12,469 shares of the business.
Falcione Aaron bought 5,500 shares of OGN for $48,235 on May 07 ’25. The Chief Human Resources Officer now owns 62,974 shares after completing the transaction at $8.77 per share. On May 06 ’25, another insider, Weaver Kirke, who serves as the Gen. Counsel & Corp. Secy. of the company, bought 8,045 shares for $9.21 each. As a result, the insider paid 74,054 and bolstered with 52,489 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OGN now has a Market Capitalization of 1648181888 and an Enterprise Value of 9945182208. As of this moment, Organon’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.35, and their Forward P/E ratio for the next fiscal year is 1.57. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26 while its Price-to-Book (P/B) ratio in mrq is 2.25. Its current Enterprise Value per Revenue stands at 1.583 whereas that against EBITDA is 5.93.
Stock Price History:
The Beta on a monthly basis for OGN is 0.53, which has changed by -0.6624068 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, OGN has reached a high of $19.05, while it has fallen to a 52-week low of $6.39. The 50-Day Moving Average of the stock is -35.05%, while the 200-Day Moving Average is calculated to be -44.34%.
Shares Statistics:
OGN traded an average of 4.78M shares per day over the past three months and 9375440 shares per day over the past ten days. A total of 259.96M shares are outstanding, with a floating share count of 259.02M. Insiders hold about 0.36% of the company’s shares, while institutions hold 82.82% stake in the company. Shares short for OGN as of 1760486400 were 12151104 with a Short Ratio of 2.54, compared to 1757894400 on 13694797. Therefore, it implies a Short% of Shares Outstanding of 12151104 and a Short% of Float of 6.23.
Earnings Estimates
Organon & Co (OGN) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.9, with high estimates of $0.98 and low estimates of $0.73.
Analysts are recommending an EPS of between $3.91 and $3.69 for the fiscal current year, implying an average EPS of $3.85. EPS for the following year is $4.04, with 6.0 analysts recommending between $4.26 and $3.7.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $1.59B to a low estimate of $1.56B. As of. The current estimate, Organon & Co’s year-ago sales were $1.58BFor the next quarter, 4 analysts are estimating revenue of $1.61B. There is a high estimate of $1.65B for the next quarter, whereas the lowest estimate is $1.57B.
A total of 6 analysts have provided revenue estimates for OGN’s current fiscal year. The highest revenue estimate was $6.33B, while the lowest revenue estimate was $6.26B, resulting in an average revenue estimate of $6.29B. In the same quarter a year ago, actual revenue was $6.4BBased on 6 analysts’ estimates, the company’s revenue will be $6.33B in the next fiscal year. The high estimate is $6.39B and the low estimate is $6.19B.
